157 related articles for article (PubMed ID: 21482970)
1. Letter by Madias regarding article, "Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial".
Madias JE
Circulation; 2011 Apr; 123(14):e403; author reply e405. PubMed ID: 21482970
[No Abstract] [Full Text] [Related]
2. Letter by Ayalloore and LeLorier regarding article, "Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial".
Ayalloore SG; LeLorier P
Circulation; 2011 Apr; 123(14):e404; author reply e405. PubMed ID: 21482971
[No Abstract] [Full Text] [Related]
3. Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
Scirica BM; Braunwald E; Belardinelli L; Hedgepeth CM; Spinar J; Wang W; Qin J; Karwatowska-Prokopczuk E; Verheugt FW; Morrow DA
Circulation; 2010 Aug; 122(5):455-62. PubMed ID: 20644019
[TBL] [Abstract][Full Text] [Related]
4. Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36).
Mega JL; Hochman JS; Scirica BM; Murphy SA; Sloan S; McCabe CH; Merlini P; Morrow DA
Circulation; 2010 Apr; 121(16):1809-17. PubMed ID: 20385930
[TBL] [Abstract][Full Text] [Related]
5. Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial.
Scirica BM; Morrow DA; Budaj A; Dalby AJ; Mohanavelu S; Qin J; Aroesty J; Hedgepeth CM; Stone PH; Braunwald E
J Am Coll Cardiol; 2009 Apr; 53(16):1411-21. PubMed ID: 19371824
[TBL] [Abstract][Full Text] [Related]
6. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
Melloni C; Newby LK
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
[TBL] [Abstract][Full Text] [Related]
7. Myocardial ischemia and ventricular tachycardia on continuous electrocardiographic monitoring and risk of cardiovascular outcomes after non-ST-segment elevation acute coronary syndrome (from the MERLIN-TIMI 36 Trial).
Harkness JR; Morrow DA; Braunwald E; Ren F; Lopez-Sendon J; Bode C; Budaj A; Scirica BM
Am J Cardiol; 2011 Nov; 108(10):1373-81. PubMed ID: 21890090
[TBL] [Abstract][Full Text] [Related]
8. Relation of T-wave alternans to mortality and nonsustained ventricular tachycardia in patients with non-ST-segment elevation acute coronary syndrome from the MERLIN-TIMI 36 trial of ranolazine versus placebo.
Nieminen T; Scirica BM; Pegler JR; Tavares C; Pagotto VP; Kanas AF; Sobrado MF; Nearing BD; Umez-Eronini AA; Morrow DA; Belardinelli L; Verrier RL
Am J Cardiol; 2014 Jul; 114(1):17-23. PubMed ID: 24852915
[TBL] [Abstract][Full Text] [Related]
9. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36).
O'Malley RG; Bonaca MP; Scirica BM; Murphy SA; Jarolim P; Sabatine MS; Braunwald E; Morrow DA
J Am Coll Cardiol; 2014 Apr; 63(16):1644-53. PubMed ID: 24530676
[TBL] [Abstract][Full Text] [Related]
10. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
Scirica BM; Morrow DA; Hod H; Murphy SA; Belardinelli L; Hedgepeth CM; Molhoek P; Verheugt FW; Gersh BJ; McCabe CH; Braunwald E
Circulation; 2007 Oct; 116(15):1647-52. PubMed ID: 17804441
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial.
Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Skene A; McCabe CH; Braunwald E;
Am Heart J; 2006 Jun; 151(6):1186.e1-9. PubMed ID: 16781216
[TBL] [Abstract][Full Text] [Related]
12. The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine.
Karwatowska-Prokopczuk E; Wang W; Cheng ML; Zeng D; Schwartz PJ; Belardinelli L
Europace; 2013 Mar; 15(3):429-36. PubMed ID: 23258816
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
[TBL] [Abstract][Full Text] [Related]
14. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial.
Morrow DA; Scirica BM; Sabatine MS; de Lemos JA; Murphy SA; Jarolim P; Theroux P; Bode C; Braunwald E
J Am Coll Cardiol; 2010 Mar; 55(12):1189-1196. PubMed ID: 20298924
[TBL] [Abstract][Full Text] [Related]
15. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial.
Arnold SV; Morrow DA; Wang K; Lei Y; Mahoney EM; Scirica BM; Braunwald E; Cohen DJ;
Circ Cardiovasc Qual Outcomes; 2008 Nov; 1(2):107-15. PubMed ID: 20031797
[TBL] [Abstract][Full Text] [Related]
16. The riddle of nonsustained ventricular tachycardia and sudden cardiac death: are we approaching a solution?
Patton KK
Circulation; 2010 Aug; 122(5):449-51. PubMed ID: 20644012
[No Abstract] [Full Text] [Related]
17. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Murphy SA; Budaj A; Varshavsky S; Wolff AA; Skene A; McCabe CH; Braunwald E;
JAMA; 2007 Apr; 297(16):1775-83. PubMed ID: 17456819
[TBL] [Abstract][Full Text] [Related]
18. Relation between thrombolysis in myocardial infarction risk score and one-year outcomes for patients presenting at the emergency department with potential acute coronary syndrome.
Weisenthal BM; Chang AM; Walsh KM; Collin MJ; Shofer FS; Hollander JE
Am J Cardiol; 2010 Feb; 105(4):441-4. PubMed ID: 20152236
[TBL] [Abstract][Full Text] [Related]
19. Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36.
Zelniker TA; Morrow DA; Scirica BM; Furtado JD; Guo J; Mozaffarian D; Sabatine MS; O'Donoghue ML
J Am Heart Assoc; 2021 Apr; 10(8):e017401. PubMed ID: 33840228
[TBL] [Abstract][Full Text] [Related]
20. Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction.
Pride YB; Appelbaum E; Lord EE; Sloan S; Cannon CP; Sabatine MS; Gibson CM;
Am J Cardiol; 2009 Aug; 104(4):475-9. PubMed ID: 19660597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
